Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Engel

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Molecular Pharmaceutics|July 25, 2022
Nanoparticle Fraught Liposomes: A Platform for Increased Antibiotic Selectivity in Multidrug Resistant BacteriaSuzan Fangary, Mohammad Abdel-Halim, Reem K Fathalla, et al.
ACS Chemical Neuroscience|November 2, 2021
Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative DiseasesYoussef Aboushady, Moustafa Gabr, Ahmed K ElHady, et al.
European Journal of Medicinal Chemistry|December 29, 2022
Discovery of novel 5-methoxybenzothiophene hydrazides as metabolically stable Clk1 inhibitors with high potency and unprecedented Clk1 isoenzyme selectivityDalia S El-Gamil, Ahmed K ElHady, Po-Jen Chen, et al.
Molecules (Basel, Switzerland)|March 6, 2021
5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular PotencyAhmed K ElHady, Dalia S El-Gamil, Po-Jen Chen, et al.
European Journal of Medicinal Chemistry|May 31, 2022
Development of novel conformationally restricted selective Clk1/4 inhibitors through creating an intramolecular hydrogen bond involving an imide linkerDalia S El-Gamil, Ahmed K ElHady, Po-Jen Chen, et al.
Archiv Der Pharmazie|January 12, 2013
Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitorsDalia S El-Gamil, Nermin S Ahmed, Bernard D Gary, et al.
Journal of Medicinal Chemistry|July 18, 2009
3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compoundsAdriana Stroba, Francis Schaeffer, Valerie Hindie, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 13, 2016
Pharmacological inhibition of protein kinase C (PKC)ζ downregulates the expression of cytokines involved in the pathogenesis of chronic obstructive pulmonary disease (COPD)Mohammad Abdel-Halim, Sarah S Darwish, Ahmed K ElHady, et al.
Chemmedchem|July 13, 2013
6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell linesMostafa M Hamed, Dalal A Abou El Ella, Adam B Keeton, et al.
Expert Opinion on Therapeutic Patents|June 23, 2026
An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present)Mennatallah Abdallah, Parthiena M Keddis, Trevina M Keddis, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Molecular Pharmaceutics|July 25, 2022
Nanoparticle Fraught Liposomes: A Platform for Increased Antibiotic Selectivity in Multidrug Resistant BacteriaSuzan Fangary, Mohammad Abdel-Halim, Reem K Fathalla, et al.
ACS Chemical Neuroscience|November 2, 2021
Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative DiseasesYoussef Aboushady, Moustafa Gabr, Ahmed K ElHady, et al.
European Journal of Medicinal Chemistry|December 29, 2022
Discovery of novel 5-methoxybenzothiophene hydrazides as metabolically stable Clk1 inhibitors with high potency and unprecedented Clk1 isoenzyme selectivityDalia S El-Gamil, Ahmed K ElHady, Po-Jen Chen, et al.
Molecules (Basel, Switzerland)|March 6, 2021
5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular PotencyAhmed K ElHady, Dalia S El-Gamil, Po-Jen Chen, et al.
European Journal of Medicinal Chemistry|May 31, 2022
Development of novel conformationally restricted selective Clk1/4 inhibitors through creating an intramolecular hydrogen bond involving an imide linkerDalia S El-Gamil, Ahmed K ElHady, Po-Jen Chen, et al.
Archiv Der Pharmazie|January 12, 2013
Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitorsDalia S El-Gamil, Nermin S Ahmed, Bernard D Gary, et al.
Journal of Medicinal Chemistry|July 18, 2009
3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compoundsAdriana Stroba, Francis Schaeffer, Valerie Hindie, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 13, 2016
Pharmacological inhibition of protein kinase C (PKC)ζ downregulates the expression of cytokines involved in the pathogenesis of chronic obstructive pulmonary disease (COPD)Mohammad Abdel-Halim, Sarah S Darwish, Ahmed K ElHady, et al.
Chemmedchem|July 13, 2013
6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell linesMostafa M Hamed, Dalal A Abou El Ella, Adam B Keeton, et al.
Expert Opinion on Therapeutic Patents|June 23, 2026
An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present)Mennatallah Abdallah, Parthiena M Keddis, Trevina M Keddis, et al.
Pageof 8